These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28922069)

  • 21. A systematic review of off-label uses of memantine for psychiatric disorders.
    Zdanys K; Tampi RR
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1362-74. PubMed ID: 18262702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost and impact of compulsivity: A research perspective.
    Hollander E; Doernberg E; Shavitt R; Waterman RJ; Soreni N; Veltman DJ; Sahakian BJ; Fineberg NA
    Eur Neuropsychopharmacol; 2016 May; 26(5):800-9. PubMed ID: 27235690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date.
    Fung LK; Hardan AY
    CNS Drugs; 2015 Jun; 29(6):453-63. PubMed ID: 26104862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of
    Lee TM; Lee KM; Lee CY; Lee HC; Tam KW; Loh EW
    Aust N Z J Psychiatry; 2021 Feb; 55(2):196-206. PubMed ID: 32900213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
    Grant JE; Chamberlain SR; Redden SA; Leppink EW; Odlaug BL; Kim SW
    JAMA Psychiatry; 2016 May; 73(5):490-6. PubMed ID: 27007062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine decreases vulnerability to develop compulsivity in high impulsive rats.
    Ansquer S; Belin-Rauscent A; Dugast E; Duran T; Benatru I; Mar AC; Houeto JL; Belin D
    Biol Psychiatry; 2014 May; 75(10):825-32. PubMed ID: 24252357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
    Yazici KU; Percinel I
    J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963
    [No Abstract]   [Full Text] [Related]  

  • 29. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

  • 30. The use of memantine in neuropsychiatric disorders: An overview.
    Lu S; Nasrallah HA
    Ann Clin Psychiatry; 2018 Aug; 30(3):234-248. PubMed ID: 30028898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperactivity and impulsivity in adult attention-deficit/hyperactivity disorder is related to glutamatergic dysfunction in the anterior cingulate cortex.
    Bauer J; Werner A; Kohl W; Kugel H; Shushakova A; Pedersen A; Ohrmann P
    World J Biol Psychiatry; 2018 Oct; 19(7):538-546. PubMed ID: 27973969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of glutamate in striatal subregions in obsessive-compulsive disorder with proton magnetic resonance spectroscopy.
    Simpson HB; Kegeles LS; Hunter L; Mao X; Van Meter P; Xu X; Kimeldorf MB; Pearlstein SL; Slifstein M; Shungu DC
    Psychiatry Res; 2015 Apr; 232(1):65-70. PubMed ID: 25715904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.
    Aman MG; Findling RL; Hardan AY; Hendren RL; Melmed RD; Kehinde-Nelson O; Hsu HA; Trugman JM; Palmer RH; Graham SM; Gage AT; Perhach JL; Katz E
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):403-412. PubMed ID: 26978327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutamate and anxiety disorders.
    Amiel JM; Mathew SJ
    Curr Psychiatry Rep; 2007 Aug; 9(4):278-83. PubMed ID: 17880858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.
    Deepmala ; Slattery J; Kumar N; Delhey L; Berk M; Dean O; Spielholz C; Frye R
    Neurosci Biobehav Rev; 2015 Aug; 55():294-321. PubMed ID: 25957927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translatable and Back-Translatable Measurement of Impulsivity and Compulsivity: Convergent and Divergent Processes.
    Voon V; Dalley JW
    Curr Top Behav Neurosci; 2016; 28():53-91. PubMed ID: 27418067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nontricyclic antidepressants: current trends in children and adolescents.
    Emslie GJ; Walkup JT; Pliszka SR; Ernst M
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):517-28. PubMed ID: 10230183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased Fear Memory and Glutamatergic Modulation in Compulsive Drinker Rats Selected by Schedule-Induced Polydipsia.
    Prados-Pardo Á; Martín-González E; Mora S; Merchán A; Flores P; Moreno M
    Front Behav Neurosci; 2019; 13():100. PubMed ID: 31133835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.